Biosimilars Pathway Has Blind Spots As FDA And Firms Begin Roadwork

Now that a pathway for approval of biosimilars has been laid out in the health care reform law, a slew of questions remain to be answered, from how FDA will implement the legislation to how the process for resolving patent disputes will play out